Free to Read
Different susceptibility to peroxisome proliferator-induced hepatocarcinogenesis in rats with polymorphic glutathione transferase genes
Toshihiro Kudo, Jumpei Asano, Takeshi Shimizu, Naoki Nanashima, Yang Fan, Miki Akita, Keizo Ookawa, Makoto Hayakari, Yoshihito Yokoyama,
Kohji Suto,
Shigeki Tsuchida,
Yoshihito Yokoyama
Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, and
Search for more papers by this authorKohji Suto
Department of Internal Medicine, Hirosaki City Hospital, 3-8-1 Ohmachi, Hirosaki 036-8004, Japan
Search for more papers by this authorCorresponding Author
Shigeki Tsuchida
Second Department of Biochemistry and
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorToshihiro Kudo, Jumpei Asano, Takeshi Shimizu, Naoki Nanashima, Yang Fan, Miki Akita, Keizo Ookawa, Makoto Hayakari, Yoshihito Yokoyama,
Kohji Suto,
Shigeki Tsuchida,
Yoshihito Yokoyama
Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, and
Search for more papers by this authorKohji Suto
Department of Internal Medicine, Hirosaki City Hospital, 3-8-1 Ohmachi, Hirosaki 036-8004, Japan
Search for more papers by this authorCorresponding Author
Shigeki Tsuchida
Second Department of Biochemistry and
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorAbstract
Although peroxisomal bifunctional enzyme (enoyl-CoA hydratase/l-3-hydroxyacyl-CoA dehydrogenase; BE) is a positive marker for peroxisome proliferation, it is completely absent or expressed very weakly in rat hepatic preneoplastic and neoplastic lesions induced by peroxisome proliferators (PP). After administration of PP for 8–15 weeks, some rats exhibit BE-negative preneoplastic foci but other rats do not. In the present study, to investigate the involvement of glutathione S-transferase (GST) M1 gene polymorphism in interindividual differences in susceptibility to PP, we developed a method to determine the genotypes of rats. We then examined whether rats with one type encoding 198Asn-199Cys (NC-type) or another encoding 198Lys-199Ser (KS-type) exhibit differences in clofibrate (CF) susceptibility. After administration of 0.3% CF for 6 weeks or more, BE-negative foci were found immunohistochemically in KS/KS-type rats, but not in NC/NC-type rats. The number of BE-negative foci in KS/KS rats was 15.3 ± 9.0 foci/cm2 of liver section after 6 weeks of CF administration, and the values did not alter thereafter. The mean areas of BE-negative foci in KS/KS rat livers increased during the period from 6 to 60 weeks. At weeks 30 and 60, almost all BE-negative foci exhibited a clear cell phenotype, a type of preneoplastic hepatic lesion. BE-negative foci were devoid of peroxisome proliferator-activated receptor α, whereas surrounding tissues were positive for the receptor. These results indicate that rats that are polymorphic for the GST M1 gene exhibit different susceptibilities to CF in vivo. (Cancer Sci 2006; 97: 703–709)
References
- 1 Svoboda DJ, Azarnoff DL. Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol 1966; 39: 442–50.
- 2 Reddy JK, Lalwani ND. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit Rev Toxicol 1983; 12: 1–58.
- 3 Lock EA, Michel AM, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol 1989; 29: 145–63.
- 4 Lazarow PB, De Duve C. A fatty acyl-CoA oxidizing system in rat liver peroxisomes: enhancement by clofibrate, a hypolipidemic drug. Proc Natl Acad Sci USA 1976; 73: 2043–6.
- 5 Reddy JK, Warren JR, Reddy MK, Lalwani ND. Hepatic and renal effects of peroxisome proliferators. Biological implications. Ann NY Acad Sci 1982; 386: 81–110.
- 6 Lee ST, Pineau T, Drago J et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995; 15: 3012–22.
- 7 Reddy JK, Rao MS. Peroxisome proliferators and cancer: mechanisms and implications. Trends Pharmacol Sci 1986; 7: 438–43.
- 8 Svoboda DJ, Azarnoff DL. Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res 1979; 39: 3419–28.
- 9 Reddy JK, Azarnoff DL, Hignite CE. Hypolipidemic hepatic peroxisome proliferators form a novel class of chemical carcinogenesis. Nature 1980; 283: 397–8.
- 10 Glauert HP, Beer D, Rao MS et al. Induction of altered hepatic foci in rats by the administration of hepatic peroxisome proliferators alone or following a single dose of diethylnitrosamine. Cancer Res 1986; 46: 4601–6.
- 11 Grasl-Kraupp B, Huber W, Putz B, Gerbracht U, Schulte-Hermann R. Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver. Cancer Res 1990; 50: 3701–8.
- 12 Satoh K, Kitahara A, Soma Y, Inaba Y, Hatayama I, Sato K. Purification, induction, and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci USA 1985; 82: 3964–8.
- 13 Sato K. Glutathione transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 1989; 52: 205–55.
- 14 Ito N, Tamano S, Shirai T. A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals. Cancer Sci 2003; 94: 3–8.
- 15 Warren JR, Simmon VF, Reddy JK. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays. Cancer Res 1980; 40: 36–41.
- 16 Gupta RC, Goel SK, Earley K, Singh B, Reddy JK. 32P-Postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro. Carcinogenesis 1985; 6: 933–6.
- 17 Reddy JK. Peroxisome proliferators and peroxisome proliferator-activated receptor α: biotic and xenobiotic sensing. Am J Pathol 2004; 164: 2305–21.
- 18 Yokoyama Y, Tsuchida S, Hatayama I et al. Loss of peroxisomal enzyme expression in preneoplastic and neoplastic lesions induced by peroxisome proliferators in rat livers. Carcinogenesis 1992; 13: 265–9.
- 19 Yokoyama Y, Tsuchida S, Hatayama I, Sato K. Lack of peroxisomal enzyme inducibility in rat hepatic preneoplastic lesions induced by mutagenic carcinogens: contrasted expression of glutathione S-transferase P form and enoyl CoA hydratase. Carcinogenesis 1993; 14: 393–8.
- 20 Grasl-Kraupp B, Huber W, Just W, Gibson G, Schulte-Hermann R. Enhancement of peroxisomal enzymes, cytochrome P-452 and DNA synthesis in putative preneoplastic foci of rat liver treated with the peroxisome proliferator nafenopin. Carcinogenesis 1993; 14: 1007–12.
- 21 Miller RT, Glover SE, Stewart WS, Corton JC, Popp JA, Cattley RC. Effect on the expression of c-met, c-myc and PPAR-α in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator Wy-14643. Carcinogenesis 1996; 17: 1337–41.
- 22 Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27: 337–84.
- 23 Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445–600.
- 24 Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293–7.
- 25 Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1990; 11: 33–6.
- 26 Katoh T, Nagata N, Kuroda Y et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 1996; 17: 1855–9.
- 27 Kumano T, Kimura J, Hayakari M, Yamazaki T, Sawamura D, Tsuchida S. Polymorphism of the glutathione transferase subunit 3 in Sprague–Dawley rats involves a reactive cysteine residue. Biochem J 2000; 350: 405–12.
- 28 Mayama J, Kumano T, Hayakari M et al. Polymorphic glutathione S-transferase subunit 3 of rat liver exhibits different susceptibilities to carbon tetrachloride: differences in their interactions with heat-shock protein 90. Biochem J 2003; 372: 611–16.
- 29 Hsu S, Raine L, Fanger H. Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981; 29: 577–80.
- 30 No authors listed. Histologic typing of liver tumors of the rat. J Natl Cancer Inst 1980; 64: 177–206.
- 31 Peeters JM, Hazendonk TG, Beuvery EC, Tesser GI. Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates. J Immunol Meth 1989; 120: 133–43.
- 32 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.
- 33 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350–4.
- 34 Nishimura S, Yokoyama Y, Nakano H et al. Decreased expression of glutathione S-transferases and increased fatty change in peroxisomal enzyme-negative foci induced by clofibrate in rat livers. Carcinogenesis 1995; 16: 1699–704.
- 35 Hasegawa R, Yoshida T, Mizoguchi Y et al. Phenotypic alteration of hepatocellular foci in rats treated with clofibrate and phenobarbital. Cancer Lett 1994; 83: 89–95.
- 36 Squire RA, Levitt MH. Report of a workshop on classification of specific hepatocellular lesions in rats. Cancer Res 1975; 35: 3214–23.
- 37 Enzmann H, Bannasch P. Potential significance of phenotypic heterogeneity of focal lesions at different stages in hepatocarcinogenesis. Carcinogenesis 1987; 8: 1607–12.
- 38 Weber E, Bannasch P. Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced by continuous oral exposure to N-nitrosomorpholine. Carcinogenesis 1994; 15: 1235–42.
- 39 Chen H, Lin RJ, Schiltz RL et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997; 90: 569–80.
- 40 Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1998; 273: 15639–45.
- 41
Fan CY,
Pan J,
Chu R et al.
Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene.
J Biol Chem
1996; 271: 24698–710.
10.1074/jbc.271.40.24698 Google Scholar
- 42 Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14643. Carcinogenesis 1997; 18: 2029–33.
- 43 Weglarz TC, Sandgren EP. Cell cross-talk mediates PPARα null hepatocyte proliferation after peroxisome proliferator exposure. Carcinogenesis 2004; 25: 107–12.
- 44 Doull J, Cattley R, Elcombe C et al. A cancer risk assessment of di(2-ethylhexyl) phthalate: application of the new US EPA Risk Assessment Guidelines. Reg Toxicol Pharmacol 1999; 29: 327–57.
- 45 DeJong JL, Chang CM, Whang-Peng J, Knutsen T, Tu CP. The human liver glutathione S-transferase gene superfamily: expression and chromosome mapping of an Hb subunit cDNA. Nucl Acids Res 1988; 16: 8541–54.
